Daniel Elger joins e-Therapeutics
pharmafile | June 13, 2011 | Appointment | Research and Development, Sales and Marketing | appointment, research and development, sales and marketing
UK and India-based e-Therapeutics has appointed Dr Daniel Elger as chief financial officer.
He joins the drug discovery company from UK biotech Antisoma, where he was VP of marketing and communications and served on its senior management team.
Prior to Antisoma Daniel was a programme director for major pharmaceutical companies at a leading marketing and communications agency.
Malcolm Young, e-Therapeutics chief executive, said, “Daniel has a wide set of skills across corporate, financial and communications areas, and he is a valuable addition to the e-Therapeutics team.
“Following our £21 million placing at the beginning of the year, implementing our strategic plans and communicating them to current and potential shareholders will be key elements of his role.”
The company also announced the departure of its finance director J.M. Cordiner, who leaves e-Therapeutics to pursue other business interests.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






